HOME >> MEDICINE >> NEWS
Once-a-month naltrexone successfully used to treat alcohol dependence

New Haven, Conn.-Long-acting injections of the drug naltrexone, combined with psychotherapy, significantly reduced heavy drinking in patients being treated for alcohol dependence, according to a study in the Journal of the American Medical Association by a Yale School of Medicine researcher.

"The decision to take medication can wane over time," said Stephanie O'Malley, professor of psychiatry and director of the Division of Substance Abuse Research at the Connecticut Mental Health Center at Yale. "This provides coverage for an entire month."

Acohol dependence ranks as the fourth leading cause of disability worldwide, as reported by the World Health Organization's Global Burden of Disease project. Nationwide, it is believed to contribute to more than 100,000 preventable deaths a year.

Naltrexone belongs to a class of drugs called opioid antagonists. Although many clinical trials have shown that oral naltrexone can be effective in treating alcohol dependence, its use in clinical practice has been limited, in part patients have to take the pill daily.

In this trial conducted at 24 sites, 627 alcohol dependent patients were randomly assigned to receive either an injection of long-acting naltrexone or a placebo injection; 624 ultimately received at least one injection. All participants received 12 counseling sessions during the six-month study in addition to the medication. Long-acting naltrexone was associated with a reduction in heavy drinking within the first month of treatment, and this response was maintained over the six month treatment period.

The lead author was James Garbult, M.D., of the University of North Carolina School of Medicine.


'"/>

Contact: Jacqueline Weaver
jacqueline.weaver@yale.edu
203-432-8555
Yale University
7-Apr-2005


Page: 1

Related medicine news :

1. Once-a-month injectable medication helps treat alcohol dependence
2. Novel catheter technique successfully patches holes in the heart
3. Study evaluates why blacks do not successfully donate kidneys
4. Magnetic probe successfully tracks implanted cells in cancer patients
5. Drug-eluting stents successfully treat vein-graft disease
6. Stem cell therapy successfully treats heart attack in animals
7. Spot on treatment for acne
8. Using coxibs and NSAIDs to treat osteoarthritis
9. New treatment boosts muscle function in myasthenia gravis
10. New treatment effective in counteracting cocaine-induced symptoms
11. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA

Post Your Comments:
(Date:9/1/2015)... ... ... For many men, the first thing they notice when they go to button their white ... fitting shirt with a collar that doesn’t close against the skin, creating a sloppy look. ... all day because it’s uncomfortable. Now men in suits will be able to do ...
(Date:9/1/2015)... ... September 01, 2015 , ... Earth Brands, ( ... fall collection. Every customer who buys an Earth Brand shoe will be given ... with Trees for the Future, a nonprofit dedicated to planting more trees. Earth ...
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty ... “The Beauty Behind the Fashion” on Thursday, Oct. 1, at the La Valencia ... the spotlight on the collaboration between fashion and professional hair, makeup and nail design. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... to efficiently cure and prevent different malignancies. Some options for cancer treatment ... properties due to which distinctive approach is necessary for effective treatment. Several ...
(Date:9/1/2015)... ... 01, 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and ... her firm’s success in the hair care and distribution industry through her combination ... will be providing “Look and learn” live demonstrations, as well as promoting her ...
Breaking Medicine News(10 mins):Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
(Date:9/1/2015)... OAKS, Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) ... (STudy evaluating effect of RomosozUmab Compared with Teriparatide ... for fracture pReviously treated with bisphosphonatE therapy). The ... statistically significant difference in favor of romosozumab in ...
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... 1, 2015  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, is scheduled to present at ... Hyatt Regency Boston in Boston, Massachusetts ... Michael A. Mussallem , Edwards Lifesciences, chief executive officer, ... a company discussion with conference attendees at 10:10 a.m. ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
Cached News: